NCT02890368: Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides |
|
|
| Terminated | 1 | 56 | US | TTI-621 Monotherapy, SIRPα-IgG1 Fc, TTI-621 + PD-1/PD-L1 Inhibitor, SIRPα-IgG1 Fc + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a, SIRPα-IgG1 Fc + pegylated interferon-α2a, TTI-621 + T-Vec, SIRPα-IgG1 Fc + talimogene laherparepvec, TTI-621 + radiation, SIRPα-IgG1 Fc + radiation | Pfizer | Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma, Squamous Cell Carcinoma, Breast Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Soft Tissue Sarcoma | 03/20 | 03/20 | | |
TRAMUNE, NCT03085225: Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. |
|
|
| Completed | 1 | 40 | Europe | Combination of trabectedin with durvalumab | Institut Bergonié, AstraZeneca, PharmaMar | Ovarian Carcinoma, Soft Tissue Sarcoma | 11/20 | 01/22 | | |
NCT03056599: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma |
|
|
| Completed | 1 | 23 | US | Multiple drug microinjection, Doxorubicin, Docetaxel, Gemcitabine, Interferon gamma, Pembrolizumab, Ipilimumab, Interferon alfa-2B, Bortezomib, Aldesleukin, Trabectedin, Eribulin, Olaratumab, Atezolizumab, Durvalumab, Avelumab, Nivolumab, Larotrectinib, Entrectinib, Avapritinib, Saline, CIVO device | Presage Biosciences, Fred Hutchinson Cancer Center, University of Washington, Northwell Health, Oregon Health and Science University | Soft Tissue Sarcoma Adult | 07/21 | 09/21 | | |
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations |
|
|
| Active, not recruiting | 1 | 200 | Europe, Japan, US, RoW | LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab | Eli Lilly and Company, Loxo Oncology, Inc. | Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor | 07/23 | 05/25 | | |
